Format

Send to

Choose Destination
Pharmacotherapy. 2015 Jul;35(7):681-6. doi: 10.1002/phar.1611. Epub 2015 Jul 3.

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.

Author information

1
School of Medicine, Loma Linda University, Loma Linda, California.
2
College of Pharmacy, Marshall B. Ketchum University, Fullerton, California.
3
School of Public Health, Loma Linda University, Loma Linda, California.

Abstract

STUDY OBJECTIVE:

To evaluate the long-term risk of developing cognitive symptoms (e.g., dementia, hallucinations), dyskinesia, falls, and freezing of gait (FoG) in patients with Parkinson's disease (PD) who received monoamine oxidase type B inhibitors (MAOB-Is) compared with patients who had never received MAOB-Is.

DESIGN:

Retrospective, cross-sectional, cohort study.

SETTING:

Academic movement disorders clinic.

PATIENTS:

One hundred eighty-one patients with idiopathic PD who were receiving MAOB-I therapy on a long-term basis for a minimum of 1 year (MAOB-I current-user cohort) and 121 patients with idiopathic PD who had never received MAOB-I therapy (MAOB-I never-user cohort [control group]) between January 1, 1996, and November 30, 2011.

MEASUREMENTS AND MAIN RESULTS:

The five study outcome variables were dementia, dyskinesia, falls, FoG, and hallucinations. Baseline and outcome data were collected from medical records. Patients in the MAOB-I current-user group were included only if absence of the specified outcomes was documented at baseline. Adjusted multiple logistic regression analyses were performed to calculate the odds ratios (ORs) for MAOB-I use versus never use on clinical outcomes. MAOB-I treatment was associated with a 44.7% reduced risk of dyskinesia (adjusted OR 0.553, 95% confidence interval 0.314-0.976, p=0.041), with the greatest risk reduction observed after 2 years of treatment. No significant association was noted with MAOB-I use and development of dementia, falls, FoG, or hallucinations.

CONCLUSION:

Long-term use of MAOB-I therapy was associated with reduced risk of dyskinesia in patients with PD.

KEYWORDS:

Parkinson's disease; dyskinesia; monoamine oxidase inhibitor; rasagiline; selegiline

PMID:
26139574
PMCID:
PMC5034746
DOI:
10.1002/phar.1611
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center